Gilead Sciences (GILD) Reports Q4 Profit Up 13% to $1.42B

Gilead Sciences Inc. (GILD) released Q4 2025 results showing net profit of $1.42 billion, a 13% increase from $1.26 billion in the same period of 2024. Revenue rose 14% year-over-year to $4.89 billion, driven by strong sales of Sovaldi and Veklury, with new HIV treatment Selzentry contributing $120 million. The company reaffirmed its guidance for 2026, citing continued growth in hepatitis C and HIV therapies.